reports
- ING Helpdesk
- Hilde Van Boxstael
- Jacob Mekhael
- Sharad Kumar S.P
- Wim Lewi
- Jacob Mekhael
MaaT Pharma FIRST LOOK: DSMB recommends MaaT033 phase 2b continues as ...
MaaT announced that the DSMB (safety board) completed its routine safety assessment of the phase 2b trial (PHOEBUS) of MaaT033 (microbiome therapy, oral capsule) in patients post allo-HSCT, and recommended continuation of the trial without modification. The trial is expected to include the last patient in 2Q26, which means a readout can be expected in 2H27. MaaT033 is next in line after lead product MaaT013 (microbiome therapy, enema formulation), and being an oral capsule means the product coul...
- Sharad Kumar S.P
Sofina Newsletter 15: NAVps up 12% y/y aided by recovery across PE & V...
ENAV grew by 12% y/y and came in at €10.1bn or €307ps. We see the NAV growth as further evidence of operational excellence of portfolio companies and rebound in both activity and valuations across PE and VC. NAV growth was mainly driven by Sofina Growth which rose, during 2H FY24, by 15.8% to ~€2.2bn. As expected, EG Software is now one of the top-10 investments in the portfolio. During FY24, Sofina invested in Cyera ($3bn valuation), Finova Capital ($728m valuation) and Vivobarefoot while parti...
MaaT Pharma annonce le résultat positif du deuxième DSMB pour l'essai ...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem TherapiesTM (MET)1 visant à améliorer la survie des patients atteints de cancers grâce à la modulation du système immunitaire, annonce que le DSMB a complété la seconde évaluation portant sur la sécurité pour l'essai de Phase 2b PHOEBUS, le plus large essai contrôlé randomisé évaluant une thérapie issue du microbiote en oncologie à ce jour, et a recommandé la poursuite de l'essai sans modification. Le D...
MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b ...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, announced that the DSMB completed its second safety assessment of the Phase 2b trial PHOEBUS, the largest randomized controlled trial assessing microbiome therapy in oncology to date, and recommended continuation of the trial without modification. The routine DSMB, which convenes every six months, is composed of 5 i...
- ING Helpdesk
- Sharad Kumar S.P
Gimv Shareholders approve potential rights issue & New growth strategy
Yesterday a second extraordinary general meeting (EGM) of Gimv took place following the no-quorum meeting of 23-Dec-2024 and Gimv's shareholders approved Gimv's strategic growth ambitions and gave the go-ahead for a possible capital increase. We note that Gimv will be hosting a CMD on 22-Jan-2025 during which, management will provide more details about its new strategy and the potential capital raise. Post capital raise, Gimv aims to double its portfolio size while helping grow some of its top i...
- Guy Sips
- Jacob Mekhael
- Michiel Declercq
- Sharad Kumar S.P
- Thomas Vranken
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Thomas Vranken
- Wim Lewi
- Jacob Mekhael
MaaT Pharma MaaT013 phase 3 beats expectations in aGvHD, MAA submissio...
MaaT announced that the phase 3 trial of MaaT013 met its primary endpoint in 3L aGvHD with a day 28 GI-ORR of 62%, exceeding our expectations and coming in in-line with our blue-sky scenario being significantly above what was observed in the phase 2 trial, and more or less in line with results from the early access program (EAP). Additionally, the company unexpectedly reported survival data showing a survival probability of 54%, higher than the 15% observed in the literature for off-label option...
- Sharad Kumar S.P
Holdings Report - December 2024 KBCS Holdings Universe Returns -3.1% d...
1M Performance - Absolute: During Dec'24 (1M period), the KBCS Holdings Universe posted a return of -3.2% which was mainly driven by multi-asset holdings (-4.3%) while single-asset holdings posted a significantly less negative return of -0.6%. The 3 top performers during the period were D'Ieteren Group (+26.6%), Compagnie du Bois Sauvage (+7.0%) and KBC Ancora (+7.0%) while the 3 worst performers were Exor (-5.4%), Heineken Holding (-3.6%) and Gimv (-1.1%). FY24 Performance - Relative: During ...
GBLB GROUPE BRUXELLES LAMBERT SA
HAL HAL TRUST
DIE D'IETEREN SA
SOF SOFINA SA
SOLV SOLVAC S.A.
GIMB GIMV NV
QFG QUEST FOR GROWTH
ACKB ACKERMANS & VAN HAAREN NV
TUB FINANCIERE DE TUBIZE S.A.
HEIO HEINEKEN HOLDING N.V.
KBCA KBC ANCORA SCA
TEXF TEXAF
BREB BREDERODE S.A.
TINC TINC COMM. VA
EXO EXOR N.V.
ROCK WHITESTONE GROUP
MaaT Pharma Announces Positive Topline Results from the Pivotal Phase ...
LYON, France--(BUSINESS WIRE)-- Regulatory News: (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today announced topline results from ARES, a pivotal, single-arm, open-label, multicenter European Phase 3 study evaluating the efficacy and safety of MaaT013 in acute Graft-versus-Host Disease patients with gastrointestinal involvement (GI-aGvHD) in third-line treatment, meaning refractory to steroids and refractor...
MaaT Pharma annonce des résultats positifs pour l'étude pivotale de Ph...
LYON, France--(BUSINESS WIRE)-- Regulatory News : (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem TherapiesTM (MET)1 visant à améliorer la survie des patients atteints de cancers grâce à la modulation du système immunitaire, annonce aujourd'hui les résultats principaux d’ARES, une étude européenne pivotale de Phase 3 multicentrique, ouverte et à un seul bras, évaluant l'efficacité et la sécurité de MaaT013 chez des patients atteints de la maladie aiguë du greffon contre l'hôte avec atteinte gastro-...
MaaT Pharma : Information mensuelle relative au nombre total de droits...
LYON, France--(BUSINESS WIRE)-- Regulatory News : (EURONEXT : MAAT - la « Société »), société de biotechnologies en stade clinique avancé, leader dans le développement de Microbiome Ecosystem TherapiesTM (MET)1 visant à améliorer la survie des patients atteints de cancers grâce à la modulation du système immunitaire, publie le nombre d'actions composant son capital et le nombre total de droits de vote (articles L. 233-8 II du code de commerce et 223-16 du règlement général de l'AMF) au 31 décembre 2024. Place de cotation : Euronext Paris Code ISIN : FR0012634822 Site web : Date ...
- ING Helpdesk
- Sharad Kumar S.P
Gimv Sale Of Majority Stake In KÖBERL Group
Gimv announced that it has sold its majority stake in KÖBERL Group (facility management and building technology services) to Hungarian company B+N Referencia Zrt. The transaction is anticipated to have a positive impact of approximately €1.0 on Gimv's NAVps and the return on this investment has significantly exceeded Gimv's long-term portfolio return target of 15.0%. This is the third transaction that Gimv has complete post its 1H results. We see this as an indication of the superior quality of ...
- Hilde Van Boxstael
- Michiel Declercq
- Sharad Kumar S.P
- Wim Hoste
- Wim Lewi
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Wim Lewi
- Jacob Mekhael
MaaT Pharma We're confident going into MaaT013's phase 3 topline in aG...
With recruitment completed for the phase 3 trial of lead program MaaT013 in aGvHD, topline data with GI-ORR is pinned for January 2025. We preview the upcoming readout and expect 15-20% upside if our base case materialises. We update our model to increase our peak sales expectations for MaaT013 in aGvHD to € 170m (from € 100m), which ups our TP to € 16 (from € 14). While this initial program represents a smaller commercial opportunity for MaaT, we see the results for MaaT013 as key to validate t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.